Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus with a pandemic spread. So far, a total of 349,910 SARS-CoV-2 cases and 7687 deaths were reported in Croatia. We analyzed the seroprevalence and neutralizing (NT) antibody response in the Croatian general population after the first (May-July 2020) and second (December 2020-February 2021) pandemic wave. Initial serological testing was performed using a commercial ELISA, with confirmation of reactive samples by a virus neutralization test (VNT). A significant difference in the overall seroprevalence rate was found after the first (ELISA 2.2%, VNT 0.2%) and second waves (ELISA 25.1%, VNT 18.7%). Seropositive individuals were detected in all age groups, with significant differences according to age. The lowest prevalence of NT antibodies was documented in the youngest (<10 years; 16.1%) and the oldest (60-69/70+ years; 16.0% and 12.8%, respectively) age groups. However, these age groups showed the highest median NT titers (32-64). In other groups, seropositivity varied from 19.3% to 21.5%. A significant weak positive correlation between binding antibody level as detected by ELISA and VNT titer (rho = 0.439, < 0.001) was observed. SARS-CoV-2 NT antibody titers seem to be age-related, with the highest NT activity in children under 10 years and individuals above 50 years.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235035PMC
http://dx.doi.org/10.3390/pathogens10060774DOI Listing

Publication Analysis

Top Keywords

seroprevalence neutralizing
8
neutralizing antibody
8
antibody response
8
pandemic wave
8
sars-cov-2 seroprevalence
4
response second
4
second covid-19
4
covid-19 pandemic
4
wave croatia
4
croatia severe
4

Similar Publications

Background: Kyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional target of 0.5% was set for seroprevalence of hepatitis B surface antigen (HBsAg) among targeted birth cohorts.

View Article and Find Full Text PDF

An incursion and outbreak of Japanese encephalitis virus (JEV) was reported in Australia in 2021 and 2022, respectively. There was speculation that JEV may have been circulating in Australia unknowingly prior to the detection. In this study, we determined sero-prevalence and transmission of West Nile virus (WNV), Murray Valley encephalitis virus (MVEV) and JEV, prior to and post JEV incursion in a sentinel equine population in south-east Queensland (SEQ), Australia, using blocking ELISAs (screening test) and virus neutralisation test (confirmatory).

View Article and Find Full Text PDF

Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently emerged tickborne virus in east Asia with over 18,000 confirmed cases. With a high case fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the NIAID. Despite this, there are currently no approved therapies or vaccines to treat or prevent SFTS.

View Article and Find Full Text PDF

BK polyomavirus (BKV) causes polyomavirus-associated nephropathy (PyVAN) and polyomavirus-associated hemorrhagic cystitis (PyVHC) following kidney transplantation and allogeneic hematopoietic stem cell transplantation (HST). BKV strains fall into four distinct genotypes (BKV-I, -II, -III, and -IV) with more than 80% of individuals are seropositive against BKV-I genotype, while the seroprevalence of the other four genotypes is lower. PyVAN and PyVHC occurs in immunosuppressed (e.

View Article and Find Full Text PDF

Disparities in anti-nucleocapsid and anti-spike SARS-CoV-2 antibody prevalence in NYC - April-October 2021.

Ann Epidemiol

December 2024

Bureau of Epidemiology Services, Center for Population Health Data Science, NYC Department of Health & Mental Hygiene, 42-09 28th St, Queens, NY 11101, USA.

Purpose: Between April-October 2021, the New York City (NYC) Health Department conducted a serosurvey to assess prevalence of SARS-CoV-2 antibodies in NYC adults as part of continued COVID-19 surveillance efforts.

Methods: Whole blood specimens were collected from 1035 adult NYC residents recruited from an annual population-based health surveillance survey. Specimens were tested for the presence of anti-SARS-CoV-2 spike protein (anti-spike) and anti-SARS-CoV-2 nucleocapsid protein (anti-nucleocapsid) antibodies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!